Prognostic Value of Sox2 Expression in Digestive Tract Cancers： A Meta-analysis

• Published in: Journal of Huazhong University of Science and Technology. Medical sciences 2016-06, Vol.36 (3), p.305-312
• Main Author: 杜小明 王留花 陈小文 李怡晓 李玉聪 曹玉文
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - therapeutic use; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Esophageal Neoplasms - diagnosis; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Gastrointestinal Tract - metabolism; Gastrointestinal Tract - pathology; Gene Expression; Humans; Medicine; Medicine & Public Health; Meta分析; Neoadjuvant Therapy - methods; Neoplasm Grading; Neoplasms, Vascular Tissue - diagnosis; Neoplasms, Vascular Tissue - drug therapy; Neoplasms, Vascular Tissue - mortality; Neoplasms, Vascular Tissue - secondary; Prognosis; PubMed; SOXB1 Transcription Factors - genetics; SOXB1 Transcription Factors - metabolism; Stomach Neoplasms - diagnosis; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Survival Analysis; 价值; 医学文献数据库; 消化道; 癌症患者; 结直肠癌; 预后
• ISSN: 1672-0733; 1993-1352
• DOI: 10.1007/s11596-016-1584-9

The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang（up to October 2014）. A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers（esophageal, gastric, and colorectal cancers）. The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas（HR=1.55, 95% CI=1.04–2.31）, especially for patients with esophageal cancer（HR=2.04, 95%CI=1.30–3.22）, colorectal cancer（HR=1.40, 95% CI=1.04–1.89）, and digestive tract adenocarcinoma（HR=1.80, 95% CI=1.12–2.89）, for Europeans（HR=1.98, 95% CI=1.44–2.71） or patients who did not receive neoadjuvant treatment（HR=1.73, 95% CI=1.10–2.72）. Furthermore, Sox2 over-expression was highly correlated with vascular invasion（OR=1.86, 95% CI=1.25–2.77） and poor differentiation（OR=1.88, 95% CI=1.14–3.08）, especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.